The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rechtsteiner, G.
Right arrow Articles by Radsak, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rechtsteiner, G.
Right arrow Articles by Radsak, M. P.
The Journal of Immunology, 2005, 174: 2476-2480.
Copyright © 2005 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod1

Gerd Rechtsteiner2,*, Tobias Warger2,*, Philipp Osterloh*,{dagger}, Hansjörg Schild3,{dagger} and Markus P. Radsak*,{dagger}

* Institute for Immunology, Johannes Gutenberg-University, Mainz, Germany; and {dagger} Department of Immunology, Institute for Cell Biology, Eberhard-Karls-University, Tübingen, Germany

CTL are important in combating cancer and viruses. Therefore, triggering the complete potential of CTL effector functions by new vaccination strategies will not only improve prophylaxis of tumor or virus-related diseases, but also open opportunities for effective therapeutic immunizations. Using transcutaneous immunization, we show that epicutaneous (e.c.)4 application of an ointment containing a CTL epitope and the TLR7 ligand imiquimod is highly effective in activating T cells in mice using TCR-transgenic CTL or in wild-type mice. Transcutaneous immunization-activated CTL mount a full-blown immune response against the target epitope characterized by proliferation, cytolytic activity, and the production of IFN-{gamma} that is completely restricted to the epitope used for vaccination. Our results obtained by simple e.c. application of an ointment, without further skin irritating procedures, provide the basis for the development of new, easy to use vaccines against cancer or virus-associated diseases.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. J.B. van Stipdonk, D. Badia-Martinez, M. Sluijter, R. Offringa, T. van Hall, and A. Achour
Design of Agonistic Altered Peptides for the Robust Induction of CTL Directed towards H-2Db in Complex with the Melanoma-Associated Epitope gp100
Cancer Res., October 1, 2009; 69(19): 7784 - 7792.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. H. Tripp, F. Sparber, I. F. Hermans, N. Romani, and P. Stoitzner
Glycolipids Injected into the Skin Are Presented to NKT Cells in the Draining Lymph Node Independently of Migratory Skin Dendritic Cells
J. Immunol., June 15, 2009; 182(12): 7644 - 7654.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Becker, V. Heib, M. Klein, F. Doener, T. Bopp, C. Taube, M. Radsak, H. Schild, E. Schmitt, and M. Stassen
Impaired Mast Cell-Driven Immune Responses in Mice Lacking the Transcription Factor NFATc2
J. Immunol., May 15, 2009; 182(10): 6136 - 6142.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
C. Othoro, D. Johnston, R. Lee, J. Soverow, J.-C. Bystryn, and E. Nardin
Enhanced Immunogenicity of Plasmodium falciparum Peptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod
Infect. Immun., February 1, 2009; 77(2): 739 - 748.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Oncologist, August 1, 2008; 13(8): 859 - 875.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Adams, D. W. O'Neill, D. Nonaka, E. Hardin, L. Chiriboga, K. Siu, C. M. Cruz, A. Angiulli, F. Angiulli, E. Ritter, et al.
Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant
J. Immunol., July 1, 2008; 181(1): 776 - 784.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Hosoi, Y. Takeda, Y. Furuichi, M. Kurachi, K. Kimura, R. Maekawa, K. Takatsu, and K. Kakimi
Memory Th1 Cells Augment Tumor-Specific CTL following Transcutaneous Peptide Immunization
Cancer Res., May 15, 2008; 68(10): 3941 - 3949.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Wang, L. S. Bursch, A. Kissenpfennig, B. Malissen, S. C. Jameson, and K. A. Hogquist
Langerin Expressing Cells Promote Skin Immune Responses under Defined Conditions
J. Immunol., April 1, 2008; 180(7): 4722 - 4727.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Stoitzner, L. K. Green, J. Y. Jung, K. M. Price, C. H. Tripp, B. Malissen, A. Kissenpfennig, I. F. Hermans, and F. Ronchese
Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells
J. Immunol., February 1, 2008; 180(3): 1991 - 1998.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Heib, M. Becker, T. Warger, G. Rechtsteiner, C. Tertilt, M. Klein, T. Bopp, C. Taube, H. Schild, E. Schmitt, et al.
Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice
Blood, August 1, 2007; 110(3): 946 - 953.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. K. Chan and J. S. Berek
Impact of the Human Papilloma Vaccine on Cervical Cancer
J. Clin. Oncol., July 10, 2007; 25(20): 2975 - 2982.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Berghofer, G. Haley, T. Frommer, G. Bein, and H. Hackstein
Natural and Synthetic TLR7 Ligands Inhibit CpG-A- and CpG-C-Oligodeoxynucleotide-Induced IFN-{alpha} Production
J. Immunol., April 1, 2007; 178(7): 4072 - 4079.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Warger, P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, and M. P. Radsak
Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo
Blood, July 15, 2006; 108(2): 544 - 550.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Stoitzner, C. H. Tripp, A. Eberhart, K. M. Price, J. Y. Jung, L. Bursch, F. Ronchese, and N. Romani
Langerhans cells cross-present antigen derived from skin
PNAS, May 16, 2006; 103(20): 7783 - 7788.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. M. Prins, N. Craft, K. W. Bruhn, H. Khan-Farooqi, R. C. Koya, R. Stripecke, J. F. Miller, and L. M. Liau
The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity
J. Immunol., January 1, 2006; 176(1): 157 - 164.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
W.-p. Kong, L. Xu, K. Stadler, J. B. Ulmer, S. Abrignani, R. Rappuoli, and G. J. Nabel
Modulation of the Immune Response to the Severe Acute Respiratory Syndrome Spike Glycoprotein by Gene-Based and Inactivated Virus Immunization
J. Virol., November 15, 2005; 79(22): 13915 - 13923.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.